Which of the following is a treatment option for Myasthenia Gravis?

Pyridostigmine is a treatment option for Myasthenia Gravis because it acts as a reversible inhibitor of the enzyme acetylcholinesterase. This results in increased levels of acetylcholine at the neuromuscular junction, thereby enhancing neuromuscular transmission and improving muscle strength. Myasthenia Gravis is characterized by weakness and fatigue of voluntary muscles due to an autoimmune attack on acetylcholine receptors. By inhibiting the breakdown of acetylcholine, pyridostigmine helps to mitigate some of these muscle weakness symptoms, making it a cornerstone therapy for this condition.

Atropine, on the other hand, is an anticholinergic agent that would actually reduce the effects of acetylcholine, thus worsening muscle weakness in Myasthenia Gravis. Dantrolene is primarily used to manage malignant hyperthermia and spasticity and does not have a role in treating Myasthenia Gravis. Mycophenolate mofetil is an immunosuppressant that can be used in refractory cases, but it is not a first-line treatment and does not directly enhance neuromuscular transmission.